Schedule of Events

2018 ASCP Annual Meeting Tentative Schedule

 *of special interest to clinicians

For a complete list of panel and workshop titles, please click here.

 Monday, May 28, 2018
 8:00 AM  New Investigator Award (NIA) Workshop (Invitation Only)
 Tuesday, May 29, 2018
 8:30 AM  Conference Opening
 9:00 AM – 10:30 AM  Panel Sessions

  Identifying Moderators of Antidepressant Treatment and Strategies to Reduce Placebo Response: Findings from the EMBARC Study*
  It’s Not Just Autism: ASD and Associated Psychopathology and Cognitive Dysfunction*
  ACTIVE Update: Reduction in World Health Organization (WHO) Drinking Risks Level as a Primary Endpoint for Alcohol Treatment Trials
  Herbal and Nutraceutical Agents for Schizophrenia: Recent Clinical Trials*
 10:30 AM – 10:45 AM  Break
 10:45 AM – 12:15 PM  Panel Sessions

  Early-Phase Trials of Novel Interventions for Treatment-Resistant Depression
  Enhancing Medication Adherence in Clinical Trials: Challenges and Opprotunities
  The Opioid Epidemic: Crisis and Solutions*
  Pharmacodynamic and Cognitive Evaluation of CNS Drugs in Clinical Trials of Cannabis and Driving Impairment
 12:15 PM – 1:45 PM  Early Career Luncheon: Work Life Balance (RSVP Only)

  Michael Davis, MD, PhD, FDA
  Katharine Phillips, MD, Weill Cornell Medical College
  Dawn Ionescu, MD, Janssen Research and Development
  Mirjana Domakonda, MD, Hartford Hospital/Institute of Living
  Ross Baker, MD, Otsuka
  Kari Nations, PhD, INC Research
 2:00 PM – 4:00 PM  Pharmaceutical Pipelines
 4:00 PM – 4:15 PM  Break
 4:15 PM – 5:30 PM  Individual Research Reports
 6:15 PM – 7:45 PM  New Investigator Awards Ceremony
 Wednesday, May 30, 2018
 6:30 AM  Annual ASCP Fun Run/Walk – Open to all attendees
 8:30 AM – 10:00 AM  Regulatory Plenary: Autism Spectrum Disorder

  John Newcomer, MD, Chair
  Tiffany Farchione, MD: FDA
  Valentina Mantua, MD: EMA
 10:00 AM – 10:15 AM  Break
 10:15 AM – 11:15 AM  ASCP Lifetime Awardee Talk
 11:15 AM – 1:00 PM  Poster Session I with Lunch
 1:00 PM – 2:30 PM  Panel Sessions

   Treatment of Resistant Depression with Ketamine: Similarities and Differences With ECT*
   Geriatric Psychopharmacology Update: Findings, Challenges, and New Opportunities*
   New Perspectives on Treatment Resistant Schizophrenia (TRS)
   Long-Term Medication for Axis I Disorders: Lifetime Treatment or Not?*
 2:30 PM – 2:45 PM  Break
 2:45 PM – 4:45 PM  Workshop Sessions

  Early Career Workshop: How to Get Published
  Joint ASCP/AFSP Workshop: Inclusion of Suicidal Individuals in Treatment Trials: Now is the Time
  FDA’s Initiatives to Optimize Pediatric Clinical Development for Psychiatric Products
  30 Years of the PANSS in Schizophrenia: Where Are We Now and Where Are We headed?
 5:00 PM – 6:00 PM  ASCP Business Meeting and Reception (Members Only)
 6:00 PM – 7:00 PM  ASCP Reception
 Thursday, May 31, 2018
 8:15 AM – 9:45 AM  Keynote Plenary

  Marlene Freeman, MD, Chair
  Sandra Comer, PhD: Opioid Use Across the Lifespan
  Helen Mayberg, MD: Strategies to Refine and Optimize DBS for Depression: A Multidisciplinary Translational Approach
  J John Mann, MD: Suicidal Behavior Across the Life Cycle
 9:45 AM – 10:00 AM  Break
 10:00 AM – 12:30 PM  Federal Agency Directors Plenary

  Michael Thase, MD, Chair
  Raye Litten, PhD: NIAAA Update
  Ivan Montoya, MD, MPH: Research Priorities of NIDA’s Medications Development Program
  Shelli Avenevoli, PhD: NIMH Updates and Research Priorities
  Richard Nakamura, PhD: CSR Update
  Miriam Smyth, PhD: VA Update
  Ronald Hoover, PhD: DoD Update
 12:30 PM – 2:00 PM  Poster Session II with Lunch
 2:00 PM – 3:30 PM Clinical Updates in Psychopharmacology Session*

  Holly Swartz, MD, Chair
  Anita Clayton, MD: Pathophysiology, Assessment, and Treatment of Sexual Dysfunction
  Rajnish Mago, MD: Which Pharmacogenomic Tests are Useful for Predicting and Reducing Adverse Effects?
  Anthony Rostain, MD: Update on Treating ADHD
 3:30 PM – 3:45 PM  Break
 3:45 PM – 5:45 PM  Workshop Sessions

  Challenges and Implementation of CNS Clinical Trials
  Leadership Skills for Mid-Career Professional
  Behavioral and Psychological Symptoms of Dementia: Perspectives in Clinical Development from the Division of Psychiatry Products, Food and Drug Administration*
  Women’s Mental Health across the Lifespan: Knowledge Gained
and Evidence Gaps*
 Friday, June 01, 2018
 8:30 AM – 10:00 AM  Panel Sessions

  Neuroplasticity and Ketamine Response in Depression
  Controversies in Bipolar Depression Across the Lifespan*
  Optimizing Signal Detection in Psychiatric Clinical Trials
  Challenges in Translating Suicidality Concepts for International Trials across the Lifespan
 10:00 AM – 10:15 AM  Break
 10:15 AM – 11:45 AM  Regulatory Wrap-Up Plenary

  John Newcomer, MD, Chair
  Tiffany Farchione, MD: FDA
  Mitchell Mathis, MD: FDA
 12:00 PM  Meeting Adjourns

 *of special interest to clinicians